5 Comments

Beyond unfathomable. Political agendas and corporate profits first, public health last. Well researched and written!

Expand full comment

Great piece, and I am so glad to have the chance to read it - despite how depressing it is that you have had to self-publish such an extensively researched, expertly reported and skilfully written story.

That NS eligibility questionnaire indicates that MAB is not available for severely immunosuppressed individuals who have had three shots already?

That seems like a policy that could make a life-saving treatment inaccessible to those who might need it most. Particularly since those immunosuppressed and most vulnerable to severe illness might be those most likely to have already had three shots.

I note that is not the policy at Dr. Chagla's clinic, where "immunosuppressed" are eligible regardless of how many shots they've had.

Expand full comment

Good point, Shannon. I know, if you look at the various eligibility requirements in different jurisdictions they all differ. It's hard to say why, maybe something to do with the current shortage of these treatments and having to make decisions around distribution? I also can't help but wonder why there is a shortage -- or if there even is one. Maybe it's more that the demand is higher than expected, and that more people--including the vaccinated-- seem to need them. Check out the Health and Human Services site in the US: there you don't even have to test positive or have symptoms to get access, you just have to be high risk. https://combatcovid.hhs.gov/possible-treatment-options-covid-19/monoclonal-antibodies-high-risk-covid-19-positive-patients

Expand full comment

Great work.. important stuff..thank you..I've been wondering why taxpayers of NS cannot know the stumpage rates Westfor mills pay us( the public) for our crown wood... perhaps you know Linda..food for thought anyways

Expand full comment

Yes, food for thought for sure. Stumpage rates are a best kept secret! I know people who know, but they won't/ can't say.

Expand full comment